COH: Cochlear Implant Leader – Quality Franchise at Peak Valuation
COH: Cochlear Implant Leader – Quality Franchise at Peak Valuation
In a Nutshell
Executive Summary
In a Nutshell
Cochlear manufactures cochlear implants and sound processors for the profoundly deaf, controlling 60% of a global market where fewer than 5% of eligible adults receive treatment. At A$199.83 versus fair value A$123, the stock trades 62% above our estimate despite franchise quality. The company sits at a trough (new product transition delays, Services revenue declining, strong Australian dollar), but current pricing already reflects a full recovery and then some.
Investor Profiles
| Profile | Rating | Rationale |
|---|---|---|
| Income | ★★★☆☆ | The 2.2% yield sits below market average but dividends are reliable—72% payout sustained through cycles with net cash fortress balance sheet. Dividend growth mirrors earnings, which compound at 5-6% over time. Suitable for income investors seeking quality over yield, but the overvaluation reduces margin of safety. |
| Value | ★☆☆☆☆ | At 32x earnings and A$200 versus A$123 fair value, this is emphatically NOT a value play. The stock trades at double the peer group multiple (15x EBITDA versus 31x) despite similar growth. Quality justifies a premium, not a 62% overvaluation. Wait for A$135-145 entry. |
| Growth | ★★☆☆☆ | Revenue growth of 5.8% (7% in constant currency) is respectable but unexciting—in line with GDP plus modest share gains. The 700,000-strong installed base compounds slowly but durably. Structural penetration runway (<5% of eligible adults treated) exists but realisation depends on surgeon supply and reimbursement policy. |
| Quality | ★★★★★ | Business quality scores 8.0/10 versus peer average 6.8—this is a textbook franchise. ROIC of 22% exceeds cost of capital by 12.5 percentage points. Wide moat from switching costs (permanent implant plus proprietary processors) and regulatory barriers lasts 7-10 years. Management credible at 8.2/10. |
| Thematic | ★★★★☆ | Aging demographics (65+ population growing 3%/year) and emerging cognition-hearing research create secular tailwinds. Emerging market formalisation (China, India government tenders growing 15%+) expands the addressable market. Healthcare defensive characteristics insulate from economic cycles. Strong thematic fit for long-term holders. |
Best Fit: Quality Investors. This stock's competitive position—60% global market share, zero churn on installed base, 40-year patient lock-in—makes it ideal for quality-focused portfolios. The 22% ROIC and widening moat from new firmware-upgradeable platform justify holding through cycles. However, quality investors must reconcile that franchise value with current 62% overvaluation. Entry at fair value or modest premium (A$130-140) would align price with quality.
Executive Summary
Cochlear manufactures cochlear implants for the profoundly deaf and sound processors that upgrade every 5-7 years—a classic razor-razorblade model. Each of 55,000 annual implants generates 40+ years of recurring upgrade revenue. The company controls 60% of a global market where penetration sits below 5%, creating a structural growth runway anchored to aging demographics.
Recent performance reflects company-specific challenges overlaying solid underlying demand. First-half FY26 revenue rose 4% despite a new product (Nexa) rollout delayed by hospital contracting and Services revenue declining 9% as customers deferred upgrades. A strong Australian dollar subtracted A$30 million from earnings. The combination created a trough, but cochlear implant unit growth remained healthy at 6% in developed markets and above 15% in emerging markets.
The investment case centres on franchise quality—this is a rare oligopoly (three players control 95% of the market) with exceptional customer lock-in and regulatory barriers. Strategic optionality exists from cognition-hearing guidelines potentially doubling the addressable market. However, quality doesn't always mean value. At A$199.83 versus fair value A$123, the stock is 62% overvalued.
Results & Outlook
What happened? First-half FY26 revenue reached A$1,176 million, up 1% reported (4% constant currency). Cochlear implant volumes grew solidly—6% in developed markets, 15%+ in emerging markets—but the new Nexa platform's hospital contracting took longer than expected, capping the benefit. Services revenue declined 9% as existing recipients delayed processor upgrades amid cost-of-living pressures. Gross margin compressed 150 basis points to 73% due to emerging market mix and Nexa launch costs. The Australian dollar at 70 US cents versus 66 cents guidance cost A$30 million.
| Metric | FY24A | FY25A | FY26E | FY27E |
|---|---|---|---|---|
| Revenue (A$M) | 2,258 | 2,356 | 2,450 | 2,670 |
| EBITDA (A$M) | 628 | 638 | 644 | 751 |
| EPS (A$) | 6.19 | 6.21 | 6.18 | 7.32 |
| CI Unit Growth (%) | 12 | 10 | 8 | 10 |
| Services Growth (%) | 6 | -9 | 2 | 8 |
| Gross Margin (%) | 75.0 | 74.0 | 73.0 | 74.0 |
What's next? The second half should show momentum. Nexa contracting accelerated through December (80% of new units) and hospital renewals approach completion. The old N7 processor retires in the US during second-half FY26, forcing an upgrade wave that should return Services to growth. Emerging market tenders continue driving volume, though at margin-dilutive pricing. Full-year guidance calls for underlying earnings at the lower end of A$435-460 million. Recovery extends into FY27 as Services inflection compounds, margins normalise toward 74%, and cloud transformation costs (A$80 million one-off) cease. Currency remains the wildcard—every cent the Australian dollar rises costs A$3 million annually.
Valuation & Risks
| Metric | Value |
|---|---|
| Fair Value | A$123 |
| Current Price | A$199.83 |
| Upside/(Downside) | (38%) |
| 80% Confidence Range | A$92 – A$154 |
What could go wrong? The Australian dollar poses the most immediate risk. At 70 US cents today versus 66 cents in guidance, translation costs A$30 million annually. The Reserve Bank's February 2026 rate hike to 3.85%—with inflation at 3.8%—supports further Australian dollar strength. If the currency sustains above 72 cents (30% probability in our assessment), another A$15 million disappears, and fair value drops A$10 per share to A$113. Unlike operational risks that management can address, currency is entirely outside the company's control and affects all ASX-listed offshore earners. Beyond currency, emerging market penetration at lower pricing threatens permanent margin compression. If emerging markets exceed 40% of unit volumes (currently 38%), gross margin could settle at 72-73% rather than the historical 74-75%, destroying 8% of fair value. Services revenue must also inflect in second-half FY26 as modelled—if cost-of-living pressures persist and recipients delay upgrades beyond FY27, the recurring revenue thesis weakens materially.